← Eichor
Condition: Estrogen Receptor Positive Tumor Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Estrogen Receptor Positive Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Phase 2 · 1 location(s) · Dana-Farber Cancer Institute · NCT07467772
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2-
Phase 3 · 1 location(s) · Genentech, Inc. · NCT07541079
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended En
Phase N/A · 12 location(s) · Shengjing Hospital · NCT04476485
Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Phase 2 · 1 location(s) · Brown University · NCT06974604
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Posit
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT06260033
PRE-I-SPY Phase I/Ib Oncology Platform Program
Phase 1 · 7 location(s) · QuantumLeap Healthcare Collaborative · NCT05868226
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestran
Phase 1/Phase 2 · 52 location(s) · Genentech, Inc. · NCT07100106
NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
Phase 2 · 8 location(s) · Swiss Cancer Institute · NCT06452394
Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
Phase 3 · 1 location(s) · Peking University · NCT02535221
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Phase 3 · 1 location(s) · Fudan University · NCT05901428
Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
Phase 2 · 12 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT05872204
Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
Phase 3 · 19 location(s) · Ente Ospedaliero Ospedali Galliera · NCT05601700
4FMFES-PET Imaging of ER+ Advanced Breast Cancers
Phase 2 · 1 location(s) · Centre de recherche du Centre hospitalier universitaire de S · NCT04824014
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Gire
Phase 1 · 4 location(s) · Genentech, Inc. · NCT07214662
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06525766
[18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer
Phase 2 · 1 location(s) · Asan Medical Center · NCT07314073
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07209449
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Phase 1 · 6 location(s) · Edgewood Oncology Inc. · NCT04872166
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic
Phase 3 · 72 location(s) · National Cancer Institute (NCI) · NCT07391774
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 · 18 location(s) · NiKang Therapeutics, Inc. · NCT07029399
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT05181033
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Phase 2 · 11 location(s) · National Cancer Institute (NCI) · NCT06184750
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth
Phase 2 · 78 location(s) · Eli Lilly and Company · NCT07287098
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Phase 2 · 1 location(s) · Kristina A. Fanucci · NCT07222215
Active Surveillance in Older Women With ER+ Breast Cancer
Phase N/A · 1 location(s) · University of Pittsburgh · NCT07262138
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Phase 2 · 2 location(s) · Baylor Breast Care Center · NCT05020860
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence
Phase 2 · 1 location(s) · Washington University School of Medicine · NCT02476786
Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
Phase 2 · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT06500208
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Parti
Phase 1/Phase 2 · 65 location(s) · Eli Lilly and Company · NCT05768139
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NA · 39 location(s) · Natera, Inc. · NCT07214532
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.